Medtronic and UK software company Brainomix are collaborating to advance stroke care for patients across Western Europe.
Medtronic will combine Brainomix’s AI-driven imaging software with its neurovascular technologies to increase access to the technology at regional hospitals and healthcare providers.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to the companies, the collaboration will support faster, more accurate stroke diagnoses and enable healthcare professionals across the region to make better-informed decisions.
Powered by AI algorithms that provide real-time interpretation of brain scans to aid treatment and transfer decisions for stroke patients, a recent study of the Brainomix 360 Stroke platform showed a doubling of thrombectomy rates for stroke treatment at Brainomix sites and an additional 37% increase compared with non-evaluation sites.
Results from the real-world study included data from more than 71,000 patients across 26 hospitals over a three-year period and were presented at the 2025 International Stroke Conference (ISC) in Los Angeles, US.
Brainomix CEO and co-founder Dr Michalis Papadakis commented: “This partnership with Medtronic is a natural fit, with the leading neurovascular device provider joining forces with the leading stroke AI imaging partner, both aligned around a mutual commitment towards improving stroke care for all patients.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“We have demonstrated that our software impacts treatment rates, and working with Medtronic, we now have an opportunity together to deliver a solution for stroke networks across Europe that will enable more patients to get access to vital stroke treatments.”
By simplifying and accelerating stroke detection and intervention, the partnership is also anticipated to alleviate the burden on healthcare providers across hospital networks in Western Europe.
The global neurovascular market, which encompasses stroke care, was worth around $4.2bn in 2024, as per GlobalData analysis.
Reports recently emerged that Johnson & Johnson (J&J) is considering the sale of Cerenovus, its neurovascular division.
According to GlobalData analysts, given that the market’s major players, including Medtronic, control approximately 68% of the global neurovascular market, it is challenging for mid-sized companies such as Cerenovus to scale effectively. With J&J’s potential exit from the space, analysts anticipate that competitors such as Medtronic may strengthen their foothold in neurovascular care to shape the future of stroke care.
